RU2005109421A - Лечение метастатического рака молочной железы антрациклинами и таксанами - Google Patents
Лечение метастатического рака молочной железы антрациклинами и таксанами Download PDFInfo
- Publication number
- RU2005109421A RU2005109421A RU2005109421/14A RU2005109421A RU2005109421A RU 2005109421 A RU2005109421 A RU 2005109421A RU 2005109421/14 A RU2005109421/14 A RU 2005109421/14A RU 2005109421 A RU2005109421 A RU 2005109421A RU 2005109421 A RU2005109421 A RU 2005109421A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- use according
- administration
- combination
- chemotherapeutic agents
- Prior art date
Links
- 229940045799 anthracyclines and related substance Drugs 0.000 title claims 4
- 206010055113 Breast cancer metastatic Diseases 0.000 title claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 13
- 229940127089 cytotoxic agent Drugs 0.000 claims 13
- -1 diphenyl compound Chemical class 0.000 claims 7
- 235000010290 biphenyl Nutrition 0.000 claims 6
- 239000004305 biphenyl Substances 0.000 claims 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 6
- 229940123237 Taxane Drugs 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229940063683 taxotere Drugs 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 125000002456 taxol group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40767902P | 2002-09-04 | 2002-09-04 | |
| US60/407,679 | 2002-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005109421A true RU2005109421A (ru) | 2005-10-20 |
Family
ID=31978506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005109421/14A RU2005109421A (ru) | 2002-09-04 | 2003-09-03 | Лечение метастатического рака молочной железы антрациклинами и таксанами |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060089317A1 (https=) |
| EP (1) | EP1536779A2 (https=) |
| JP (1) | JP2006516533A (https=) |
| KR (1) | KR20050086415A (https=) |
| CN (1) | CN1694691A (https=) |
| AU (1) | AU2003266047A1 (https=) |
| BR (1) | BR0314097A (https=) |
| CA (1) | CA2497180A1 (https=) |
| MX (1) | MXPA05002465A (https=) |
| RU (1) | RU2005109421A (https=) |
| WO (1) | WO2004022040A2 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2063574T3 (es) * | 1990-12-17 | 1995-01-01 | Univ Manitoba | Metodo de tratamiento mejorado para el cancer. |
| GB9303210D0 (en) * | 1993-02-17 | 1993-03-31 | Univ Manitoba | Cancer treatment |
| PL369792A1 (en) * | 2001-11-01 | 2005-05-02 | Ym Biosciences, Inc. | Use of n,n-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy |
| US20050119263A1 (en) * | 2001-11-09 | 2005-06-02 | Vincent Mark D. | Treatment of breast cancer |
-
2003
- 2003-09-03 CA CA002497180A patent/CA2497180A1/en not_active Abandoned
- 2003-09-03 JP JP2004533120A patent/JP2006516533A/ja not_active Withdrawn
- 2003-09-03 CN CNA038247461A patent/CN1694691A/zh active Pending
- 2003-09-03 AU AU2003266047A patent/AU2003266047A1/en not_active Abandoned
- 2003-09-03 WO PCT/CA2003/001340 patent/WO2004022040A2/en not_active Ceased
- 2003-09-03 US US10/526,563 patent/US20060089317A1/en not_active Abandoned
- 2003-09-03 MX MXPA05002465A patent/MXPA05002465A/es unknown
- 2003-09-03 KR KR1020057003797A patent/KR20050086415A/ko not_active Ceased
- 2003-09-03 BR BR0314097-0A patent/BR0314097A/pt not_active IP Right Cessation
- 2003-09-03 RU RU2005109421/14A patent/RU2005109421A/ru not_active Application Discontinuation
- 2003-09-03 EP EP03793535A patent/EP1536779A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1536779A2 (en) | 2005-06-08 |
| KR20050086415A (ko) | 2005-08-30 |
| JP2006516533A (ja) | 2006-07-06 |
| AU2003266047A8 (en) | 2004-03-29 |
| WO2004022040A2 (en) | 2004-03-18 |
| BR0314097A (pt) | 2005-07-19 |
| CN1694691A (zh) | 2005-11-09 |
| AU2003266047A1 (en) | 2004-03-29 |
| CA2497180A1 (en) | 2004-03-18 |
| MXPA05002465A (es) | 2005-12-14 |
| WO2004022040A3 (en) | 2004-04-29 |
| US20060089317A1 (en) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ506187A (en) | Use of epothilones for the treatment of cancer | |
| US20090069394A1 (en) | Cancer treatment with epothilones | |
| OA12819A (en) | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer. | |
| JP2007511498A (ja) | Ｅｔ−７４３とドキソルビシンとを使用することを含むガンの併用療法 | |
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| ES2278702T3 (es) | Composicion para el tratamiento de metastasis o del cancer, que contiene fluorouracilo y un agente de transferencia de metilol. | |
| RU2005109421A (ru) | Лечение метастатического рака молочной железы антрациклинами и таксанами | |
| RU2007104176A (ru) | Синтез и применение (-)-бета-элемена, (-)-бета-элеменала, (-)-бета-элеменола, фторида (-)-бета-элемена и их аналогов, а также промежуточных продуктов и композитов | |
| JP2005512996A5 (https=) | ||
| RU2005110401A (ru) | Применение комбинаци dppe с другими химиотерапевтическими агентами для лечения рака молочной железы | |
| JP2006516532A5 (https=) | ||
| KR20070089158A (ko) | 암의 치료를 위한ｎ-(3-메톡시-5-메틸피라진-2-일)-2-(4-[1,3,4-옥사디아졸-2-일]페닐)피리딘-3-설폰아미드 및 항-유사분열제의 조합물 | |
| US20080318880A1 (en) | Neoadjuvant treatment of Breast Cancer | |
| CN100402029C (zh) | 包含埃坡霉素衍生物和烷化剂的组合 | |
| EP0793499B1 (en) | Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound | |
| JP2006516533A5 (https=) | ||
| AU2004251444B2 (en) | Cancer treatment with epothilones | |
| JP2008519808A5 (https=) | ||
| WO2004022044A1 (en) | Use of a combination of a taxane with dppe for the treatment of cancer | |
| KR20110104932A (ko) | Ａｖｅ８０６２ 및 도세탁셀이 조합된 항종양 조합물 | |
| RU2008100229A (ru) | Лечение метастазирующих опухолей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080130 |